Enclomifene - Repros Therapeutics

Drug Profile

Enclomifene - Repros Therapeutics

Alternative Names: Androxal; Enclomid; Enclomifene citrate; Enclomiphene; Enclomiphene citrate; trans-clomifene; Trans-clomiphene; Trans-clomiphene-citrate

Latest Information Update: 31 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Repros Therapeutics
  • Class Antineoplastics; Diethylamines; Ethanolamines; Small molecules; Stilbenes
  • Mechanism of Action Estrogen receptor antagonists; Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Hypogonadism
  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 26 Jan 2018 Committee for Medicinal Products for Human Use recommends refusal of marketing authorisation for enclomifene for Secondary hypogonadism in European Union
  • 15 Dec 2017 Repros Therapeutics is likely to receive negative opinion from the CHMP for enclomiphene for Hypogonadism in European Union
  • 01 Jun 2017 Repros Therapeutics completes a phase II trial in overweight men with acquired hypogonadotropic Hypogonadism in USA (NCT02651688)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top